Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:CASNumber |
gptkb:129938-20-1
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:Roche
|
| gptkbp:effect |
reactivates p53 pathway
|
| gptkbp:hasMolecularFormula |
C28H32ClN7O
|
| https://www.w3.org/2000/01/rdf-schema#label |
RG7112
|
| gptkbp:intendedUse |
anticancer agent
|
| gptkbp:IUPACName |
gptkb:4-[(3R,4S)-4-(4-chlorophenyl)-3,4-dihydro-2(1H)-quinazolinyl]-N-(4-methyl-1-piperazinyl)benzamide
|
| gptkbp:mechanismOfAction |
MDM2 inhibitor
|
| gptkbp:molecularWeight |
518.05 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:studiedBy |
leukemia
solid tumors |
| gptkbp:synonym |
gptkb:RG-7112
RO5045337 |
| gptkbp:target |
gptkb:MDM2_protein
|
| gptkbp:bfsParent |
gptkb:MDM2
|
| gptkbp:bfsLayer |
6
|